JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation - Takeaways - MDSpire

JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation

  • By

  • Zhan-Qun Yang

  • Ning Ding

  • Meng-Zhu Zheng

  • Jian Wen

  • Yuan Xue

  • Li-Ting Zheng

  • Yi-Heng Yang

  • Cheng-He Shi

  • Hua Jiang

  • Jian Lin

  • Long Chen

  • May 11, 2026

  • 0 min

Share

  • 1

    The JinHuangJieDu (JHJD) formula effectively inhibits SARS-CoV-2 infection by blocking the RBD-ACE2 interaction.

  • 2

    JHJD demonstrates superior efficacy against both wildtype and Omicron variants of SARS-CoV-2.

  • 3

    Network pharmacology identified 375 ingredients and 338 targets related to JHJD's antiviral and anti-inflammatory effects.

  • 4

    JHJD modulates HIF-1α to alleviate inflammation caused by SARS-CoV-2 infection.

  • 5

    The dual action of JHJD positions it as a promising therapeutic candidate for COVID-19 treatment.

Original Source(s)

JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation

  • by Zhan-Qun Yang, Ning Ding, Meng-Zhu Zheng, Jian Wen, Yuan Xue, Li-Ting Zheng, Yi-Heng Yang, Cheng-He Shi, Hua Jiang, Jian Lin, Long Chen

  • May 11, 2026

Related Content

“Who’s on Backup?”—Exploring Internal Medicine Residency Backup Coverage Systems: Findings from a National Survey

The latest developments on Ebola, hepatitis B, long Covid

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study